Teva settles ‘pay-to-delay’ case with FTC

pharmafile | February 21, 2019 | News story | Business Services, Sales and Marketing FTC, Teva, antitrust, drugs, generics, monopoly 

Teva Pharmaceuticals has settled a dispute with the Federal Trade Commission (FTC) over three separate federal court antitrust lawsuits involving the firm’s subsidiary Cephalon.

The settlement comes after Teva was made to pay the FTC $1.2 billion over so-called ‘pay-to-delay’ policies in which the firm was accused of participating in blocking the entry of generic drugs into the market by receiving payments from companies producing branded drugs tin return for delaying generics market entry.

The FTC claimed that deals in which generic drugmakers are paid to stay off the market violate antitrust laws.

“This settlement represents another milestone in the Commission’s unwavering commitment to put an end to harmful reverse-payment agreements,” said FTC Chairman Joe Simons. “This broad settlement prevents the world’s largest manufacturer of generic drugs from entering into collusive agreements that prevent price competition by keeping generic drugs off the market.”

The agreement will see Teva be prohibited from entering into a payment infringement settlement agreement that includes a reverse payment transferring value from the brand to the generic. Meanwhile the FTC will dismiss its claims against Teva and its affiliates in three outstanding cases. Teva will not pay any more money to the FTC.

“We are very pleased to put these litigations against the FTC behind us. We also appreciate the FTC’s willingness to modify our consent decree to eliminate certain administrative burdens that will make it easier for us to navigate the patent issues that are critical to our business,” said Brendan O’Grady, a Teva executive vice president.

Louis Goss

Related Content


Gilead agrees to pay $97 million to settle Medicare kickbacks case

Gilead has agreed to pay $97 million to resolve claims from the US Government that …

Leading pharmaceutical companies sued in US for conspiring to drive up generics prices

26 pharmaceutical companies are being sued by most US states for allegedly conspiring to reduce …

Coronavirus pandemic puts UK’s post-Brexit drug stockpile at risk

The pharmaceutical industry has warned the UK government that certain stockpiles of medicine have been …

Latest content